Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10035352 | 1.00 | OXTR (0.51) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL10035339 | 0.97 | OXTR (0.47) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL10035329 | 0.89 | HPGD (0.51) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL10035350 | 0.86 | OXTR (0.69) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL10035326 | 0.86 | OXTR (0.69) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL10035319 | 0.85 | AVPR1A (0.56) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL10035330 | 0.85 | AVPR1A (0.56) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL398821 | 0.85 | AVPR1A (0.56) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL10035355 | 0.85 | SMN1; SMN2 (0.55) | OXTRGLAHPGDSMN1; SMN2AVPR1A | |
| SCHEMBL10035335 | 0.84 | AVPR1A (0.49) | OXTRGLAHPGDSMN1; SMN2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101771-B2 | Triazole derivative, and light-emitting element, light-emitting device, and electronic device using triazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101771-B2 | Triazole derivative, and light-emitting element, light-emitting device, and electronic device using triazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20100079066-A1 | Triazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Triazole Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100079066-A1 | Triazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Triazole Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100079066-A1 | Triazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Triazole Derivative | TTI1, TTI2, NLRP3 | OXTR 3599/4885GLA 2899/4885HPGD 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.